Ocugen (OCGN) Total Current Liabilities (2014 - 2026)
Ocugen (OCGN) reported Total Current Liabilities of $20.7 million for Q1 2026, up 22.63% on a YoY basis from $16.9 million in Q1 2025, and down 10.13% quarter-over-quarter from $23.0 million in Q4 2025.
Ocugen (OCGN) Total Current Liabilities (2014 - 2026) Analysis & Trends
Ocugen has reported Total Current Liabilities for 13 years, with the latest figure at $20.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 22.63% year-over-year to $20.7 million; the trailing twelve-month figure through Mar 2026 stood at $20.7 million (up 22.63% YoY), and the FY2025 full-year result was $23.0 million, up 6.74% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $20.7 million, down from $23.0 million in the prior quarter.
- The five-year high for Total Current Liabilities was $28.5 million in Q4 2022, with the low at $13.3 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $20.2 million across 5 years, with a median of $19.7 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 307.59% — and 2023, when it slumped 40.1%.
- Ocugen's Total Current Liabilities stood at $28.5 million in 2022, then tumbled by 40.1% to $17.1 million in 2023, then gained by 26.33% to $21.6 million in 2024, then grew by 6.74% to $23.0 million in 2025, then declined by 10.13% to $20.7 million in 2026.
- The last three Total Current Liabilities figures came in at $20.7 million (Q1 2026), $23.0 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - | 20.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.71 Mn |
| Dec 31, 2025 | 23.04 Mn |
| Sep 30, 2025 | 20.36 Mn |
| Jun 30, 2025 | 17.99 Mn |
| Mar 31, 2025 | 16.89 Mn |
| Dec 31, 2024 | 21.59 Mn |
| Sep 30, 2024 | 15.76 Mn |
| Jun 30, 2024 | 17.97 Mn |
| Mar 31, 2024 | 16.05 Mn |
| Dec 31, 2023 | 17.09 Mn |
| Sep 30, 2023 | 19.73 Mn |
| Jun 30, 2023 | 24.50 Mn |
| Mar 31, 2023 | 26.58 Mn |
| Dec 31, 2022 | 28.53 Mn |
| Sep 30, 2022 | 24.52 Mn |
| Jun 30, 2022 | 17.96 Mn |
| Mar 31, 2022 | 13.30 Mn |
| Dec 31, 2021 | 7.00 Mn |
| Sep 30, 2021 | 6.23 Mn |
| Jun 30, 2021 | 4.84 Mn |